Trials / Recruiting
RecruitingNCT07253688
Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus (RIFA-SNAP)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- Sponsor
- Todd C. Lee MD MPH FIDSA · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifampin | Patients will receive rifampin 900mg a day in 2-3 divided doses |
| OTHER | No rifampin | Subjects will be assigned to not receive adjunctive rifampin |
Timeline
- Start date
- 2025-11-10
- Primary completion
- 2029-12-01
- Completion
- 2030-07-01
- First posted
- 2025-11-28
- Last updated
- 2025-12-10
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT07253688. Inclusion in this directory is not an endorsement.